MDTMedtronic plc
- Next report
- Nov 24
- Tuesday, in 12 days · before the market opens
- EPS expected
- $1.34
- quarter ending Oct 31, 2026
- Last result
- $1.55Missed
- vs $1.58 expected on Jun 3
- Stock move on it
- +5.69%
- one session
- Price
- $101.00
- −0.61% today · $112B cap
Past and upcoming reports
2
| Nov 24, 2026 | Oct 31, 2026 | Before the market opens | $1.34 | not yet | |
| Jun 3, 2026 | Apr 30, 2026 | Before the market opens | $1.58 | Missed$1.55 | +5.69% |
Pre-earnings read
No pre-earnings read for this report
None for this company right now.
After the report
Jun 3, 2026 report
Medtronic reports in-line Q4 EPS of $1.55. shares slightly up post-earnings
Medtronic's Q4 EPS came in at $1.55, marginally below the $1.56 estimate, with shares rising 0.1% post-report. Guidance tone was neutral, reflecting steady revenue growth but ongoing risks from the diabetes unit spinoff and neuromodulation recall.
Reported against expected
EPS of $1.55 was in-line with consensus estimate of $1.56, a -0.64% surprise.
Guidance
KeptManagement maintained a neutral guidance tone amid spinoff and recall uncertainties.
How the stock reacted
Shares rose modestly by 0.1% on the day of the earnings release.
What changed
Q4 EPS was $1.55, slightly below estimate, with neutral guidance amid spinoff and recall risks.
What the price now assumes
The 0.1% share price rise reflects cautious optimism despite in-line EPS and ongoing operational risks.
What it means for the business
Maintain current view. monitor upcoming earnings and spinoff impact for growth clarity.
The next one to three months, as we saw it then
Better case30%
Spinoff proceeds smoothly, neuromodulation recall impact diminishes, enabling renewed growth acceleration.
Base case50%
Steady revenue growth continues with manageable spinoff and recall headwinds, EPS growth remains moderate.
Worse case20%
Spinoff complications and recall issues intensify, pressuring growth and investor confidence, leading to earnings misses.
If you hold it
Hold MDT unless next-quarter guidance falls below current expectations or recall issues worsen materially.
If you are watching
Consider entry if upcoming earnings show clear spinoff progress and stable recall resolution. avoid if guidance weakens or new risks emerge.
Scenario odds are a judgement, not measured.